Earnings Call transcript for Earnings Call held on May 20, 2026, for the Audited Standalone and Consolidated financial results for the quarter and year ended March 31, 2026.
ANTHEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Anthem Biosciences delivered a strong FY26 with consolidated revenue of Rs. 2,280 crores (18% YoY growth), driven by CRDMO contributing Rs. 1,773 crores (83% of revenue). EBITDA reached Rs. 990 crores with 43.4% margins (420 bps improvement YoY), while PAT grew 31% to Rs. 592 crores. Q4 FY26 was the highest revenue quarter at Rs. 611 crores with 48.1% EBITDA margins. Management highlighted that destocking headwinds are largely behind them with restocking underway. The company is investing Rs. 1,200 crores over FY27-28 in Unit 4 expansion, which will double custom synthesis capacity. Two new direct big pharma relationships were added and are expected to broaden. Backward integration completed helped gross margin improvement. Phase 3 pipeline has 10 molecules, 4 new commercial launches contributed ~8-9% of revenue. Biotech funding recovery of ~50% YoY is supporting early-stage project inquiries.
Strong profitability growth with EBITDA and PAT up 31% demonstrates operational leverage. Capacity expansion and new big pharma relationships position the company for sustained 20%+ growth. High cash position of Rs. 1,375 crores provides flexibility for inorganic opportunities.